title: Drug-Related Adverse Events of Osteoporosis Therapy.
abstract: Postmenopausal osteoporosis is associated with microarchitectural deterioration and increased risk of fracture. Osteoporosis therapy effectively reduces the risk of vertebral, nonvertebral, and hip fracture and has been associated with increased survival. Currently approved treatments for osteoporosis include bisphosphonates, denosumab, selective estrogen receptor modulators, and teriparatide. This article reviews the adverse events of therapy associated with these medical interventions. Hormone replacement therapy is not included, because it is no longer indicated for the treatment of osteoporosis in all countries. Calcitonin and strontium ranelate are also not included, because their indication for osteoporosis has recently been limited or withdrawn.
authors.affiliation: McMaster University, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada.
authors.forename: Moin
authors.initials: M
authors.lastname: Khan
authors.affiliation: University of Toronto, 200 Elizabeth Street, 7 Eaton North Room 221, Toronto, ON M5G 2C4, Canada.
authors.forename: Angela M
authors.initials: AM
authors.lastname: Cheung
authors.affiliation: McMaster University, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada. Electronic address: Aliya@mcmaster.ca.
authors.forename: Aliya A
authors.initials: AA
authors.lastname: Khan
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D000069448:Denosumab / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D019379:Teriparatide / Q000009:adverse effects*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019379:Teriparatide; D000069448:Denosumab
keywords: Atypical femoral fractures; Bisphosphonates; Denosumab; Osteonecrosis of the jaw; Raloxifene; Teriparatide